Last reviewed · How we verify

NCT03802149: U-Prep

Ulipristal Acetate for Cervical Preparation

Completed EARLY_PHASE1 Last updated 1 July 2020
What this trial tests

EARLY_PHASE1 trial testing Ulipristal Acetate in Termination of Pregnancy in 13 participants. Completed in 2 April 2020.

Timeline
16 April 2019
Primary endpoint
2 April 2020
2 April 2020

Quick facts

Lead sponsorStanford University
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment13
Start date16 April 2019
Primary completion2 April 2020
Estimated completion2 April 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

18 and older, female only, with Termination of Pregnancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective cohort study exploring a broadened use of ulipristal acetate as a cervical preparation agent for second trimester surgical abortion. Specifically, this pilot study will test the feasibility of using ulipristal as a pharmacologic cervical preparation with adjunct misoprostol prior to surgical abortion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ulipristal Acetate

Trials testing the same drug.

Other recruiting trials for Termination of Pregnancy

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03802149.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing